Shopping Cart
Remove All
Your shopping cart is currently empty
Desglymidodrine (ST 1059) is a selective α1-adrenoceptor agonist and an active metabolite of Midodrine. It is a vasoconstrictor that can be used for cardiovascular research and neurocardiogenic syncope.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $34 | - | In Stock | |
| 5 mg | $77 | - | In Stock | |
| 10 mg | $123 | - | In Stock | |
| 25 mg | $222 | - | In Stock | |
| 50 mg | $313 | - | In Stock | |
| 100 mg | $467 | - | In Stock | |
| 200 mg | $669 | - | In Stock |
| Description | Desglymidodrine (ST 1059) is a selective α1-adrenoceptor agonist and an active metabolite of Midodrine. It is a vasoconstrictor that can be used for cardiovascular research and neurocardiogenic syncope. |
| Targets&IC50 | α1D-adrenoceptor (rat):5.78 (pKi), α2A-adrenoceptor (human):5.83 (pKi), α1A-adrenoceptor (rat):5.89 (pKi), α1B-adrenoceptor (rat):5.16 (pKi) |
| In vitro | Desglymidodrine affects venoconstriction over a concentration range of 1-1000 μM, with a pD2 value of 4.64 (-log mol/L) in isolated canine femoral veins and 4.48 (-log mol/L) in isolated human saphenous veins. [1] Desglymidodrine binds to α1A, α1B, and α1D adrenergic receptors in rats and α2A adrenergic receptors in humans, corresponding to pKi values of 5.89, 5.16, 5.78, and 5.83, respectively. [2] |
| Synonyms | ST1059, ST 1059 |
| Molecular Weight | 197.23 |
| Formula | C10H15NO3 |
| Cas No. | 3600-87-1 |
| Smiles | OC(C1=CC(OC)=CC=C1OC)CN |
| Relative Density. | 1.145 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40.00 mg/mL (202.81 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (10.14 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.